Arcellx Inc (NASDAQ: ACLX) closed the day trading at $66.82 up 1.52% from the previous closing price of $65.82. In other words, the price has increased by $+1.00 from its previous closing price. On the day, 709958 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of ACLX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.77. For the most recent quarter (mrq), Quick Ratio is recorded 6.06 and its Current Ratio is at 6.06. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on January 04, 2024, Reiterated its Buy rating but revised its target price to $71 from $65 previously.
On December 19, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $66.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 12 when Elghandour Rami sold 11,169 shares for $64.46 per share. The transaction valued at 719,948 led to the insider holds 92,339 shares of the business.
Heery Christopher sold 2,967 shares of ACLX for $191,251 on Feb 12. The CHIEF MEDICAL OFFICER now owns 30,303 shares after completing the transaction at $64.46 per share. On Feb 09, another insider, Elghandour Rami, who serves as the insider of the company, sold 13,886 shares for $63.40 each. As a result, the insider received 880,340 and left with 103,508 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACLX now has a Market Capitalization of 3.47B and an Enterprise Value of 2.86B. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.67 while its Price-to-Book (P/B) ratio in mrq is 7.20. Its current Enterprise Value per Revenue stands at 25.96 whereas that against EBITDA is -44.65.
Stock Price History:
Over the past 52 weeks, ACLX has reached a high of $70.05, while it has fallen to a 52-week low of $26.32. The 50-Day Moving Average of the stock is 59.33, while the 200-Day Moving Average is calculated to be 43.93.
Shares Statistics:
Over the past 3-months, ACLX traded about 558.03K shares per day on average, while over the past 10 days, ACLX traded about 455.18k shares per day. A total of 52.28M shares are outstanding, with a floating share count of 36.99M. Insiders hold about 29.24% of the company’s shares, while institutions hold 75.53% stake in the company. Shares short for ACLX as of Feb 15, 2024 were 3.56M with a Short Ratio of 6.38, compared to 3.93M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.85% and a Short% of Float of 7.68%.
Earnings Estimates
Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of -$0.54 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.95, while EPS last year was -$0.58. The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.24 and low estimates of -$1.
Analysts are recommending an EPS of between -$0.23 and -$4.1 for the fiscal current year, implying an average EPS of -$2.11. EPS for the following year is -$2.09, with 13 analysts recommending between $1.35 and -$4.6.
Revenue Estimates
7 analysts predict $19.59M in revenue for the current quarter. It ranges from a high estimate of $34.7M to a low estimate of $15M. As of the current estimate, Arcellx Inc’s year-ago sales were $17.91M, an estimated increase of 9.40% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $19.66M, a decrease of -51.50% less than the figure of $9.40% in the same quarter last year. There is a high estimate of $34.7M for the next quarter, whereas the lowest estimate is $15M.
A total of 12 analysts have provided revenue estimates for ACLX’s current fiscal year. The highest revenue estimate was $188M, while the lowest revenue estimate was $59.8M, resulting in an average revenue estimate of $89.89M. In the same quarter a year ago, actual revenue was $110.32M, down -18.50% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $113.05M in the next fiscal year. The high estimate is $279.75M and the low estimate is $60M. The average revenue growth estimate for next year is up 25.80% from the average revenue estimate for this year.
